C07K2319/73

FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONS
20220056087 · 2022-02-24 ·

The current invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly ordered multimeric fractions, termed stradomers. In comparison to the homodimeric fraction, purified multimeric stradomers have higher affinity and avidity for FcγRs with slower dissociation and are useful in the treatment and prevention of disease. The current invention demonstrates that directly linking IgG1 Fc regions to multimerization domains leads to enhanced multimerization and biological activity.

COMPOSITION BASED ON RECOMBINANT BIOPOLYMERS AND USES OF SAME AS BIO-INK

The present invention refers to compositions comprising recombinant biopolymers made of combinations of monomers of the type “Elastin-like recombinamers” (ELR), monomers comprising the “silk” sequence and/or monomers comprising the HLF sequence that belongs to a natural class of proteins named zippers. Said compositions are useful as bio-ink for 3D printing. Furthermore, the present invention also refers to methods for obtaining the composition of the invention, as well as the 3D biomaterial and to the different uses of the composition and the obtained biomaterial.

Charged peptide appendage to facilitate oriented protein covalent immobilization

Genetic fusions of proteins, for example single-domain antibodies (sdAbs), with a positively-charged domain enhanced immobilization of active protein in a desired orientation.

VIRALLY EXPRESSED INHIBITORS OF PDZ DOMAINS, SUCH AS PICK1 AND USES THEREOF

The present invention relates to virally expressed peptides with high affinity for the PDZ domains, such as the PDZ domain of PICK1. The invention furthermore relates to the therapeutic use of these peptides in prevention and/or treatment of diseases and/or disorders associated with maladaptive plasticity and/or transmission.

Methods of Purifying Masked Antibodies

The present invention relates to the field of antibody formulations. In particular, the present invention relates to specific methods of preparing masked antibodies with reduced aggregation. In some embodiments, the masked antibodies comprise anti-CD47 antibodies.

COMPLEX FOR INTRACELLULAR DELIVERY OF MOLECULES

A fusion protein and a complex containing same, capable of being used for the intracellular delivery of cargo molecules. The fusion protein and complex can implement the efficient release of cargo molecules from endocytic vesicles, thereby significantly improving the cytoplasmic delivery efficiency of the cargo molecules. One cargo molecules can be obtained in cytoplasms, they can exert any function related thereto. The fusion protein and complex provide effective means for affecting biological mechanisms and pathways of cells, and can be used in various fields such as research, treatment, and diagnosis.

Proximity-based sortase-mediated protein purification and ligation

The invention relates to proximity-based sortase-mediated protein purification and ligation. Specifically, the invention relates to techniques that links protein expression/purification with conjugation to therapeutic agents, imaging agents, or linkers.

Immune-cell targeted bispecific chimeric proteins and uses thereof

The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by chimeric proteins which comprise modified signaling agents two or more targeting moieties. Methods of treatment and pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.

ONCOLYTIC VIRUSES & METHODS OF USE THEREOF
20170319639 · 2017-11-09 ·

Modified and improved oncolytic viruses (and methods of use thereof) are disclosed. More particularly, modified and oncolytic human herpesviruses (and methods of use thereof) are disclosed, which include a modified amino acid sequence that includes a deletion in a region that represents the amino terminus of glycoprotein K. The modified and oncolytic human herpesviruses include a deletion of amino acid residues 31-68, relative to the wild type amino acid sequence of glycoprotein K in human herpesviruses. Isolated vector constructs that encode such oncolytic viruses are also disclosed. In addition, methods for using such oncolytic viruses to treat cancers are disclosed.

PROXIMITY-BASED SORTASE-MEDIATED PROTEIN PURIFICATION AND LIGATION

The invention relates to proximity-based sortase-mediated protein purification and ligation. Specifically, the invention relates to techniques that links protein expression/purification with conjugation to therapeutic agents, imaging agents, or linkers.